Palatin Technologies (PTN) risk factors

46 risks, 19 new, 22 dropped, 7 reworded since the prior year. Strategy shifted toward early-stage MC4R agonists for rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome.

60 risks, 3 new, 2 dropped, 4 reworded since the prior year. Palatin faces severe delisting risks from the NYSE American due to low stock price. The company partnered with Boehringer Ingelheim for retinal disease treatments, introducing dependency on partner milestones. Accumulated deficit reached $459.1 million with a $17.3 million net loss in fiscal 2025.

59 risks. Palatin Technologies faces severe going concern doubts, relying heavily on additional financing to complete clinical trials for its melanocortin receptor agonists. The company sustained a net loss of $29.7 million for fiscal 2024, bringing its accumulated deficit to $441.8 million. Operations depend entirely on third-party contract manufacturers and research organizations for product supply and trial execution.